Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL5203008 | 0.94 | TACR2 (0.56) | TACR2 | |
| Citric Acid SCHEMBL7044779 | 0.94 | TACR2 (0.56) | TACR2 | |
| SCHEMBL5203217 | 0.93 | TACR2 (0.60) | TACR2 | |
| SCHEMBL5203214 | 0.93 | TACR2 (0.60) | TACR2 | |
| Citric Acid SCHEMBL5203228 | 0.92 | TACR2 (0.54) | TACR2 | |
| Citric Acid SCHEMBL5232527 | 0.90 | TACR2 (0.56) | TACR2 | |
| SCHEMBL29395251 | 0.87 | TACR2 (0.72) | TACR2 | |
| SCHEMBL1387902 | 0.87 | TACR2 (0.72) | TACR2 | |
| SCHEMBL1387904 | 0.87 | TACR2 (0.72) | TACR2 | |
| Citric Acid SCHEMBL7045674 | 0.86 | TACR2 (0.55) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444220-B1 | COMPOUNDS AND METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | claimed |
| US-20040248914-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1450805-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030187255-A1 | Therapeutic heterocycles | MILLER SCOTT CARSON (US) | 2003-10-02 | — | — | US | disclosed |
| WO-2003037341-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-6444809-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2002-09-03 | — | — | US | disclosed |
| US-6124279-A | NEUROKININ A ANTAGONISTS, ANTIASTHMATIC AGENTS | ZENECA LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| US-5990130-A | NOVEL 4-SUBSTITUTED PIPERIDINE DERIVATIVES WHICH ANTAGONIZE NEUROKININ; USEFUL IN TREATMENT OF ASMTHMA AND RELATED CONDITIONS | ZENECA LIMITED (GB) | 1999-11-23 | — | — | US | disclosed |
| US-5567700-A | USEFUL FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1996-10-22 | — | — | US | disclosed |
| EP-0714392-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248914-A1 | Method for the treatment of overactive bladder | TACR1, TACR2, OGFR | TACR2 2/4885 |
| US-20030187255-A1 | Therapeutic heterocycles | BDKRB2, TK2, TACR2 | TACR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.